Point-of-care testing kit for the early sepsis prognosis
Sepsis causes a systemic inflammatory response driven by proinflammatory cytokines and is the leading cause of death in hospital critical care units. Early disease biomarkers are necessary to assist in the decision-making identification of immunocompromised patients. The development of a point-of-care testing kit to enable quick and reliable detection of immunocompromised patients by using blood biomarkers would improve the early prognosis of sepsis. Recently, an in vitro prognostic product was developed that enables the fast detection of early impairment of the NLRP3 inflammasome activation, as a prognostic biomarker in sepsis. The objective of the current EU-funded SPEDI-TEST project is to demonstrate the technical and commercial feasibility, and evaluate the new business opportunity of the clinical introduction of this novel test.
Field of science
- /medical and health sciences/clinical medicine/critical care medicine
- /natural sciences/computer and information sciences/data science/data mining
Call for proposal
See other projects for this call